drugset / Trial / NCT05994807
A Drug-Drug Interaction Study to Assess the Pharmacokinetics of DC-806 When Orally Administered Alone, When Coadministered With Itraconazole, and When Coadministered With Carbamazepine in Healthy Adult Participants
Phase 1
Completed
33 enrolled
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
Non-randomizedParallel-groupOpen-labelBasic science
Summary
The primary objective of this study is to assess the effect of a cytochrome P450 3A4 (CYP3A4) inhibitor (itraconazole) and CYP3A4 inducer (carbamazepine) on the single dose pharmacokinetics (PK) of DC-806 coadministered with itraconazole or carbamazepine in healthy male and female participants.
Timeline
- Start
- 2023-08-08
- Primary completion
- 2023-09-20
- Completion
- 2023-09-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carbamazepine | Small molecule | — | Oral |
| Subject | DC-806 | Unknown | — | Oral |
| Subject | Itraconazole | Small molecule | — | Oral |
Indications
No indication recorded.